Edible composition and application thereof

Abstract

The invention discloses an edible composition and application thereof, and the edible composition comprises the following components in parts by mass: 10-2900 parts of probiotics; 10 to 450 parts of magnesium salt; 1 part to 100 parts of banana powder; wherein the value range of the total thallus amount of the probiotics is 3 billion CFU / g to 5 billion CFU / g. The edible composition has the beneficial effects that the edible composition of a multi-element system integrating microorganisms, mineral substances and plant active ingredients and the application of the edible composition are provided.

Description

Technical Field

[0001] This application relates to the field of functional food technology, and more specifically, to an edible composition and its application. Background Technology

[0002] The gut-brain axis (GBA), as a crucial pathway for bidirectional communication between the gut and the central nervous system, has become a research hotspot in the interdisciplinary field of neurogastroenterology and nutritional psychiatry in recent years. Numerous studies have shown that gut microbiota can significantly influence brain function and emotional state through various mechanisms, including the biosynthesis of neurotransmitters (such as GABA and 5-HT), the metabolic regulation of short-chain fatty acids (SCFAs), the regulation of immune inflammatory pathways, and the maintenance of intestinal barrier function. This, in turn, can regulate psychological problems such as anxiety and depression, and indirectly alleviate closely related gastrointestinal dysfunctions (such as irritable bowel syndrome, functional bloating, and abdominal pain).

[0003] Currently, a variety of mood-regulating functional products based on probiotics or single nutrients have appeared on the market. Therefore, developing a mood-gut bidirectional regulatory product based on natural ingredients, with a scientific synergistic mechanism, and easily accepted by consumers has become an urgent need in the current health field. Summary of the Invention

[0004] The summary section of this application is intended to provide a brief overview of the concepts, which will be described in detail in the detailed description section below. This summary section is not intended to identify key or essential features of the claimed technical solutions, nor is it intended to limit the scope of the claimed technical solutions.

[0005] Some embodiments of this application propose an edible composition and its application to solve the technical problems mentioned in the background section above.

[0006] As a first aspect of this application, some embodiments of this application provide an edible composition comprising, by weight parts: Probiotics: 10 to 2900 servings; Magnesium salts: 10 to 450 parts; Banana powder: 1 to 100 servings; The total bacterial count of the probiotics ranges from 3 billion CFU / g to 50 billion CFU / g.

[0007] Optionally, in some embodiments of this application, the probiotics include one or more of the following: Bifidobacterium longum subsp. Rosell@-175, Bifidobacterium longum 1714, Lactobacillus paracasei Lpc-37, Lactobacillus plantarum CECT7481, Lactobacillus plantarum P-8, Lactobacillus plantarum CECT7481, Lactobacillus rhamnosus HN001, and Bifidobacterium animalis subsp. lactis HN01.

[0008] Optionally, in some embodiments of this application, the total bacterial count of the probiotics ranges from 20 billion CFU / g to 50 billion CFU / g.

[0009] Optionally, in some embodiments of this application, the magnesium salt includes one or more of the following: magnesium glycinate, magnesium citrate, magnesium malate, magnesium aspartate, magnesium lactate, magnesium gluconate, magnesium taurate, magnesium threonate, magnesium orotic acid, magnesium hydroxide, magnesium carbonate, and magnesium oxide.

[0010] Optionally, in some embodiments of this application, the mass percentage of magnesium in the edible composition ranges from 0.5% to 50%.

[0011] Optionally, in some embodiments of this application, the banana powder is made from ripe banana fruit and / or banana peel.

[0012] Optionally, in some embodiments of this application, the mass percentage of banana powder ranges from 0.01% to 10%.

[0013] Optionally, in some embodiments of this application, the edible composition is prepared as at least one of powder, capsule, solid beverage, soft drink, soft capsule, liquid, powder, tablet, granule, and drops.

[0014] Optionally, in some embodiments of this application, the edible composition is prepared as a portion of at least one of powder, capsule, solid beverage, soft drink, soft capsule, liquid, powder, tablet, granule, and drops. As a second aspect of this application, some embodiments of this application provide an application of the above-described edible composition as a food product, said food product including at least: chocolate, fudge, jelly, filled chocolate, beverage, and coffee. The beneficial effects of this application are: to provide an edible composition and its application that integrates microorganisms, minerals and plant active ingredients into a multi-system.

[0015] More specifically, some embodiments of this application may produce the following specific beneficial effects: Establish a synergistic system of "probiotics-happiness factor-magnesium": probiotics promote the absorption and conversion of neurotransmitter precursors, magnesium enhances nerve conduction and stress stability, and banana powder provides natural neuromodulatory substances and dietary fiber. The three work together to improve the efficiency of neurotransmitter synthesis and utilization. Establish a mutually beneficial mechanism between probiotics and magnesium: magnesium enhances the intestinal colonization resistance of probiotics, and probiotics optimize the bioavailability of magnesium, forming a positive cycle; Achieving bidirectional synchronous regulation of the mood-gut axis: This composition can not only alleviate anxiety-depressive-like behaviors, but also effectively improve gastrointestinal dysfunction symptoms such as constipation, achieving overall health benefits through synchronous regulation of mind and body. Attached Figure Description

[0016] The accompanying drawings, which form part of this application, are used to provide a further understanding of the application and to make other features, objects, and advantages of the application more apparent. The illustrative embodiments and descriptions of this application are used to explain the application and do not constitute an undue limitation of the application.

[0017] Furthermore, throughout the accompanying drawings, the same or similar reference numerals denote the same or similar elements. It should be understood that the drawings are schematic, and the elements are not necessarily drawn to scale.

[0018] In the attached diagram: Figure 1 This is a schematic diagram of the steps in a method for preparing an edible composition according to an embodiment of this application; Figure 2 This is a schematic diagram of the steps of a banana powder preparation method according to an embodiment of this application. Detailed Implementation

[0019] Embodiments of this disclosure will now be described in more detail with reference to the accompanying drawings. While some embodiments of this disclosure are shown in the drawings, it should be understood that this disclosure can be implemented in various forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided to provide a more thorough and complete understanding of this disclosure. It should be understood that the accompanying drawings and embodiments of this disclosure are for illustrative purposes only and are not intended to limit the scope of protection of this disclosure.

[0020] It should also be noted that, for ease of description, only the parts relevant to the invention are shown in the accompanying drawings. Unless otherwise specified, the embodiments and features described in this disclosure can be combined with each other.

[0021] It should be noted that the concepts of "first" and "second" mentioned in this disclosure are used only to distinguish different devices, modules or units, and are not used to limit the order of functions performed by these devices, modules or units or their interdependencies.

[0022] It should be noted that the terms "a" and "a plurality of" used in this disclosure are illustrative rather than restrictive, and those skilled in the art should understand that, unless otherwise expressly indicated in the context, they should be understood as "one or more".

[0023] The names of messages or information exchanged between multiple devices in the embodiments of this disclosure are for illustrative purposes only and are not intended to limit the scope of such messages or information.

[0024] This disclosure will now be described in detail with reference to the accompanying drawings and embodiments.

[0025] As a first aspect of this application, some embodiments of this application provide an edible composition comprising, by weight parts: probiotics: 10 to 2900 parts; magnesium salts: 10 to 450 parts; banana powder: 1 to 100 parts; wherein the total number of probiotic cells ranges from 3 billion CFU / g to 50 billion CFU / g.

[0026] As a more specific embodiment, some embodiments of this application provide an edible composition comprising, by weight parts: probiotics: 10g / unit mass to 2900g / unit mass; magnesium salts: 10g / unit mass to 450g / unit mass; banana powder: 1g / unit mass to 100g / unit mass; wherein the total bacterial count of the probiotics ranges from 3 billion CFU / g to 50 billion CFU / g. More specifically, the unit mass ranges from 0.05g to 2.5g, preferably from 0.05g to 2g, 0.05g to 0.6g, or 0.2g to 0.4g.

[0027] Reference Figures 1 to 2 As shown, the preparation method of the edible composition of this application mainly includes the following steps: S1: Raw material pretreatment Magnesium salts (such as magnesium glycinate and magnesium citrate) and banana powder are pulverized and sieved to ensure uniform particle size. Passing through an 80-100 mesh sieve is preferred to facilitate subsequent uniform mixing. S2: Initial Mixing Add the pretreated magnesium salt and banana powder to a mixer and mix at low speed. The mixing time is preferably 15-30 minutes, until a uniform powder matrix is ​​formed.

[0028] S3: Probiotic introduction and final mixing Add the probiotics to the powder matrix obtained in step 2) and mix. Mixing conditions: low speed, short time, preferably 5-15 min, ambient temperature ≤25℃, relative humidity ≤30%, to ensure the activity of probiotics.

[0029] S4: Packaging The mixed final product is rapidly dispensed into aluminum foil bags or other high-barrier packaging materials, nitrogen-filled, and sealed. In some embodiments of this application, the probiotics include one or more of the following: *Bifidobacterium longum* subsp. *longum* Rosell@-175, *Bifidobacterium longum* 1714, *Lactobacillus paracasei* Lpc-37, *Lactobacillus plantarum* CECT7481, *Lactobacillus plantarum* P-8, *Lactobacillus plantarum* CECT7481, *Lactobacillus rhamnosus* HN001, and *Bifidobacterium animalis* subsp. *lactobacterium* HN01.

[0030] Specifically, the probiotic *Lactobacillus helveticus* is one or more of the following strains in combination: Rosell®-52 (*Lactobacillus helveticus* R0052), *Bifidobacterium longum* subsp. *Rosell@-175* (*Bifidobacterium longum* R0175), *Bifidobacterium longum* 1714™, *Lactobacillus paracasei* Lpc-37, *Lactobacillus plantarum* CECT7481, *Lactobacillus plantarum* P-8, *Lactobacillus plantarum* CECT7481, *Lactobacillus rhamnosus* HN001, and *Bifidobacterium animalis* subsp. *lactospirum* HN01.

[0031] In this application, the probiotics may be in the form of live bacteria, inactivated bacteria, or bacterial fragments. It is preferred to use live bacteria preparations processed with microencapsulation technology to improve the survival rate and colonization ability of the gastrointestinal tract.

[0032] The total number of probiotics in the composition is not less than 3 billion CFU / g, preferably not less than 10 billion CFU / g, more preferably not less than 15 billion CFU / g, and most preferably in the range of 200 CFU / g to 50 billion CFU / g, so as to achieve significant intestinal flora regulation and neuroactive substance secretion effects.

[0033] In some embodiments of this application, the total bacterial count of probiotics ranges from 20 billion CFU / g to 50 billion CFU / g.

[0034] In some embodiments of this application, the magnesium salt includes one or more of the following: magnesium glycinate, magnesium citrate, magnesium malate, magnesium aspartate, magnesium lactate, magnesium gluconate, magnesium taurate, magnesium threonate, magnesium orotic acid, magnesium hydroxide, magnesium carbonate, and magnesium oxide.

[0035] In some embodiments of this application, the mass percentage of magnesium in the edible composition ranges from 0.5% to 50%.

[0036] More specifically, in this application, the magnesium salt is selected from organic magnesium forms or complex magnesium salts with high bioavailability, including but not limited to: magnesium glycinate, magnesium citrate, magnesium malate, magnesium aspartate, magnesium lactate, magnesium gluconate, magnesium taurate, magnesium threonate, magnesium orotate, etc.; inorganic magnesium salts such as magnesium hydroxide, magnesium carbonate, and magnesium oxide may also be used in combination with other excipients.

[0037] The amount of magnesium salt added is not less than 10 mg / unit mass based on elemental magnesium, preferably not less than 30 mg / unit mass, and more preferably 100 mg / unit mass to 450 mg / unit mass, so as to fully exert its supporting effect on nerve conduction, HPA axis regulation and intestinal smooth muscle function.

[0038] In some embodiments of this application, the banana powder is made from ripe banana fruit and / or banana peel.

[0039] In some embodiments of this application, the mass percentage of banana powder ranges from 0.01% to 10%.

[0040] Specifically, banana powder is made from ripe banana fruit and / or banana peel, preferably from whole, unrotten banana fruit (including pulp and peel) or banana peel alone. Its preparation process includes the following steps: S10: Raw material pretreatment: Fresh banana raw materials are processed by physical peeling or mechanical cutting.

[0041] S20: Low temperature drying: A segmented freeze-drying process is adopted. First, it is pre-frozen at -30℃ to -40℃ for 2 to 4 hours, and then dried at a vacuum of 10Pa to 50Pa and a temperature gradient of 25℃→40℃→60℃ for 12 to 18 hours. The duration of each gradient can be evenly distributed.

[0042] S30: Ultrafine grinding: The dried material is pulverized to a particle size ≤50μm using an air jet mill, and then sterilized using microwave-assisted sterilization (power 300W to 500W, time 60 to 90 seconds). Furthermore, when banana peel is used as raw material, an additional enzymatic hydrolysis step is required: enzymatic hydrolysis with cellulase and pectinase (mass ratio 1:2) at pH 4.5 and 50℃ for 2 hours to improve the yield of soluble components.

[0043] This process preserves the polyphenols and dietary fiber in banana raw materials to the greatest extent, and the final product has a moisture content of ≤5% and a water solubility index of ≥85%.

[0044] The banana powder content of this application is not less than 1 mg / serving; as a further option, not less than 10 mg / serving; as a further option, not less than 100 mg / serving.

[0045] In some embodiments of this application, the edible composition is prepared as at least one of powder, capsule, solid beverage, soft drink, soft capsule, liquid, powder, tablet, granule, and drops.

[0046] In some embodiments of this application, the edible composition is prepared as a portion of at least one of powder, capsule, solid beverage, soft drink, soft capsule, liquid, powder, tablet, granule, and drops. As a second aspect of this application, some embodiments of this application provide an application of the above-described edible composition as a food product, the food product including at least: chocolate, gummy candy, jelly, filled chocolate, beverage, and coffee.

[0047] That is, the products of the compositions in this application can be in various dosage forms, including but not limited to common health food and dietary supplement dosage forms, such as powders, capsules, solid beverages, soft drinks, soft capsules, liquids, powders, tablets, granules, drops, and can also be common food dosage forms, such as chocolate, gummies, jelly, filled chocolates, beverages, coffee, etc.

[0048] The various dosage forms of the products for treating and / or improving anxiety and stress, as well as improving gut health, as described in this application can be prepared according to conventional manufacturing methods for pharmaceuticals, health foods, general foods, daily chemicals, feed, additives, etc. One or more carriers from the components are mixed and then prepared into the desired dosage form.

[0049] The composition described in this application is not only suitable for improving anxiety and depression, but also for stress-induced gastrointestinal disorders. It can also be used to improve mood, sleep, irritable bowel syndrome, constipation, bloating, abdominal pain, and diarrhea, demonstrating broad application prospects and market value.

[0050] Beneficial effects (Note: Please clearly state the beneficial effects of this application compared to the prior art.) Probiotics improve anxiety and gastrointestinal function through a bidirectional regulatory mechanism along the gut-brain axis. They can regulate the balance of gut microbiota, inhibit the proliferation of harmful bacteria, promote the production of short-chain fatty acids (SCFAs, such as butyrate and propionic acid), enhance intestinal barrier function, and reduce the release of inflammatory factors. At the same time, SCFAs act on the central nervous system through the vagus nerve and blood circulation, promoting the synthesis of neurotransmitters such as serotonin (5-HT) and gamma-aminobutyric acid (GABA), thus relieving anxiety. In addition, they also improve gut microbiota, forming a healthy gastrointestinal ecosystem.

[0051] Magnesium, as a natural antagonist of NMDA receptors and a positive regulator of GABA receptors, inhibits excessive excitation of the central nervous system, reduces cortisol levels, and regulates the activity of the hypothalamus-pituitary-adrenal axis (HPA axis), thereby relieving stress. It can also relieve constipation by activating calmodulin-dependent kinase, relaxing intestinal smooth muscle, and promoting intestinal peristalsis and water absorption, thus improving intestinal transit function. In addition, magnesium neutralizes excess gastric acid in the intestines, optimizes the digestive environment, reduces bloating and indigestion, and compensates for the limitations of probiotics: its effects do not depend on intestinal flora homeostasis, and it is still effective for patients with dysbiosis or leaky gut syndrome, and it has a faster onset of action (direct ion absorption) without relying on microbial metabolic transformation.

[0052] Banana powder further compensates for the limitations of probiotics and magnesium. It is rich in serotonin and dopamine, directly promoting feelings of happiness. The dietary fiber in banana powder helps maintain stable blood sugar levels, preventing mood swings. Its plant-based ingredients are extremely safe.

[0053] The present application will be further described below with reference to specific embodiments.

[0054] In the following examples and comparative examples, the unit mass is 2g. In addition to the components listed in each example and comparative example, the rest are excipients used for flavoring, such as sorbitol, erythritol, vitamin C, fructooligosaccharides, galactooligosaccharides, isomaltooligosaccharides, L-arabinose, stachyose, fruit powder, etc., including but not limited to the above excipients.

[0055] Example 1: A composition comprising probiotics Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotic content is 3 billion CFU / unit mass, the magnesium content is 30 mg / unit mass, and the banana powder content is 1 mg / unit mass.

[0056] It should be noted that among the probiotics Lactobacillus helveticus Rosell®-5 and Bifidobacterium longum subsp. Rosell®-175, Rosell®-5 and Rosell®-175 are specific product types, and their specific raw material selections are sources well known to those skilled in the art, and will not be elaborated here.

[0057] Example 2: A composition comprising probiotics Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotic content is 10 billion CFU / unit mass, the magnesium content is 250 mg / unit mass, and the banana powder content is 10 mg / unit mass.

[0058] Example 3: A composition comprising probiotics Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotic content is 30 billion CFU / unit mass, the magnesium content is 450 mg / unit mass, and the banana powder content is 100 mg / unit mass.

[0059] Example 4: A composition comprising the probiotic Lactobacillus rhamnosus HN001, Bifidobacterium animalis subsp. lactis HN019, magnesium citrate, and banana powder, wherein the probiotic content is 5 billion CFU / unit mass, the magnesium content is 50 mg / unit mass, and the banana powder content is 10 mg / unit mass.

[0060] Example 5: A composition comprising the probiotic Lactobacillus rhamnosus HN001, Bifidobacterium animalis subsp. lactis HN019, magnesium hydroxide, and banana powder, wherein the probiotic content is 9 billion CFU / unit mass, the magnesium content is 300 mg / unit mass, and the banana powder content is 10 mg / unit mass.

[0061] Example 6: A composition comprising probiotic Lactobacillus plantarum CECT7481, magnesium oxide, and banana powder, wherein the probiotic content is 3 billion CFU / unit mass, the magnesium content is 30 mg / unit mass, and the banana powder content is 1 mg / unit mass.

[0062] Example 7: A composition comprising Bifidobacterium longum 1714, magnesium sulfate and banana powder, wherein the probiotic content is 3 billion CFU / unit mass, the magnesium content is 30 mg / unit mass, and the banana powder content is 1 mg / unit mass.

[0063] Example 8: A composition comprising Lactobacillus paracasei Lpc-37, magnesium malate, and banana powder, wherein the probiotic content is 3 billion CFU / unit mass, the magnesium content is 30 mg / unit mass, and the banana powder content is 1 mg / unit mass.

[0064] Example 9: A composition comprising Lactobacillus plantarum HEAL9, magnesium aspartate and banana powder, wherein the probiotic content is 3 billion CFU / unit mass, the magnesium content is 30 mg / unit mass, and the banana powder content is 1 mg / unit mass.

[0065] Example 10: A composition comprising Lactobacillus plantarum P-8, magnesium gluconate and banana powder, wherein the probiotic content is 3 billion CFU / unit mass, the magnesium content is 30 mg / unit mass, and the banana powder content is 1 mg / unit mass.

[0066] Example 11: A composition comprising Lactobacillus rhamnosus HN001, Bifidobacterium animalis subsp. lactis HN019, Lactobacillus plantarum CECT7481, magnesium glycine, and banana powder, wherein the mixed bacterial powder content is 12 billion CFU / unit mass, the magnesium content is 300 mg / unit mass, and the banana powder content is 10 mg / unit mass.

[0067] Example 12: A composition comprising Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotics are inactivated bacteria with a cell count of 3 billion cells / unit mass, the magnesium content is 30 mg / unit mass, and the banana powder content is 1 mg / unit mass.

[0068] Example 13: A composition comprising Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotics are inactivated bacteria with a cell count of 10 billion cells / unit mass, the magnesium content is 300 mg / unit mass, and the banana powder content is 10 mg / unit mass.

[0069] Example 14: A composition comprising Lactobacillus rhamnosus HN001, Bifidobacterium animalis subsp. lactis HN019, magnesium glycine, and banana powder, wherein the probiotics are inactivated bacteria with a cell count of 9 billion cells / unit mass, the magnesium content is 300 mg / unit mass, and the banana powder content is 10 mg / unit mass.

[0070] Example 15: A composition comprising Lactobacillus rhamnosus HN001, Bifidobacterium animalis subsp. lactis HN010, Lactobacillus plantarum CECT7481, magnesium glycine, and banana powder, wherein the probiotics are inactivated bacteria with a cell count of 12 billion cells / unit mass, the magnesium content is 300 mg / unit mass, and the banana powder content is 10 mg / unit mass.

[0071] Example 16: A composition comprising Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. Rosell®-175, magnesium glycine, and banana powder, wherein the bacterial powder is 10 billion CFU / g, the magnesium glycine is 300 mg / g, and the banana powder is 10 mg / g.

[0072] Example 17: A composition comprising Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the bacterial powder is 10 billion CFU / g, the magnesium glycine is 300 mg / g, and the banana powder is 10 mg / g.

[0073] Comparative Example 1: A mixed bacterial powder containing Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum subsp. longum Rosell®-175, with a bacterial powder content of 10 billion CFU / g unit mass.

[0074] Comparative Example 2: A mixed bacterial powder containing a combination of probiotics and magnesium. The probiotics are Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum subsp. longum Rosell®-175, with a bacterial count of 10 billion CFU / unit mass. The magnesium is magnesium glycine with a content of 300 mg / unit mass.

[0075] Comparative Example 3: A composition comprising probiotics Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotic content is 30 billion CFU / unit mass, the magnesium content is 10 mg / unit mass, and the banana powder content is 100 mg / unit mass.

[0076] Comparative Example 4: A composition comprising probiotics Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotic content is 30 billion CFU / unit mass, the magnesium content is 20 mg / unit mass, and the banana powder content is 100 mg / unit mass.

[0077] Comparative Example 5: A composition comprising probiotics Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotic content is 30 billion CFU / unit mass, the magnesium content is 500 mg / unit mass, and the banana powder content is 100 mg / unit mass.

[0078] Comparative Example 6: A composition comprising probiotics Lactobacillus helveticus Rosell®-52, Bifidobacterium longum subsp. longum Rosell®-175, magnesium glycine, and banana powder, wherein the probiotic content is 30 billion CFU / unit mass, the magnesium content is 750 mg / unit mass, and the banana powder content is 100 mg / unit mass.

[0079] Mice were used to conduct a control experiment on the above-described embodiments.

[0080] Mouse anxiety behavior detection Twelve-week-old male rats were selected. One week before the model construction began, the rats were acclimatized to an unfamiliar environment. The day before model construction began, the rats underwent an elevated cruciate maze test to screen for rats with normal mental and emotional states. Rats with normal indicators were excluded for further experiments. Husbandry conditions: 12-hour light-dark cycle, free access to food and water. The screened rats were divided into a control group, an experimental group, and a positive control group, with no fewer than eight rats in each group. The rats were restrained to induce anxiety under stress. The model was established for 7 days.

[0081] Control group rats: were not restrained and were given physiological saline.

[0082] Experimental group rats: were restrained and given the samples from Examples 1-17 (200 mg / kg).

[0083] Positive control group rats: were restrained and given diazepam 1 mg / kg.

[0084] The rats were subjected to anxiety-like behavior testing using an elevated cruciate maze. The rats were placed in the central area facing the open arms, and the number of times the rats entered the open arms within 5 minutes was recorded (one time was counted as the rats entering with all four limbs completely); the percentage of time spent in the open arms (the lower the anxiety, the longer the time); and the total movement distance.

[0085] The experimental results are shown in Table 1, which presents the anxiety behavior results for different embodiments.

[0086] Table 1

[0087] As shown in Table 1, the combination of specific probiotics, magnesium, and banana powder increased the number of times the experimental group rats entered the open arm to a certain extent compared with the control group. The increase in the number of entries indicated that the rats' anxiety behavior was reduced.

[0088] Meanwhile, the open arm dwell time of the rats in the example group significantly tended to be that of the positive control group, indicating a reduction in anxiety levels in the rats, and the effect was superior to the use of probiotics alone and / or the combination of probiotics and magnesium. There was no significant difference in total movement distance among the control group, the example group, and the positive control group, suggesting that the composition's effect on improving anxiety-like behavior is specific, rather than produced by affecting the animals' spontaneous activity ability.

[0089] Comparative Examples 3 and 4 showed that the degree of anxiety improvement in mice increased with increasing magnesium content.

[0090] Comparative studies 5 and 6 showed that further increases in magnesium content did not further enhance the improvement in anxiety behavior in mice. (Mouse antidepressant experiment) Twelve-week-old rats were used and housed in a controlled environment with free access to food and water. After one week of acclimatization, the rats were randomly divided into 18 groups according to a randomized block design: a blank control group, a fluoxetine group (effective control group), and groups 1-17. The sample groups were administered 220 mg / kg of the corresponding sample via gavage, the control group was administered the same volume of purified water via gavage, and the fluoxetine group was administered the same volume of fluoxetine solution (effective dose 1 mg / kg) via gavage. Administration continued for three weeks.

[0091] Homemade open-field reaction chamber: 28cm high, 40cm long at the bottom, black-coated inside, with the bottom surface divided into 25 small squares. Water container: 20cm x 15cm, water depth 11cm; water temperature 25℃. Male rats, 12 weeks old, 8 rats per group. The experiment was conducted on day 20 1 hour after administration of the drug.

[0092] Open field test: An open field reaction chamber was prepared. One rat was placed in each open chamber and its center square was positioned, and then observed. Two evaluators assessed the activity of one rat over 5 minutes, recording the number of squares it traversed from the center of the bottom surface. After each rat's experiment, the apparatus was cleaned with detergent. Each rat was tested only once.

[0093] Swimming experiment: Rats were first trained to swim for 10 minutes, and then tested 24 hours later. Each rat was placed individually in a water container and allowed to acclimatize for 2 minutes. The cumulative immobility time (s) within 4 minutes was recorded. Immobility was defined as the rat ceasing to struggle or floating in the water, with only minor limb movements to keep its head afloat. Each rat underwent the experiment only once.

[0094] The mean values ​​of the results of spontaneous activity measurement and immobility time measurement of mice in each experimental group are shown in Table 2. Table 2 shows the results of depressive behavior in different embodiments.

[0095] Table 2

[0096] As shown in Table 2, compared with the blank control group, there was almost no difference in spontaneous activity among the rats in each group, ruling out false positives regarding the shortened immobility time during forced swimming. After forced swimming, compared with the blank control group, each embodiment significantly shortened the immobility time during forced swimming in rats, indicating that the product provided by this invention has an antidepressant effect, and its effect is superior to using probiotics alone and / or the combination of probiotics and magnesium.

[0097] Comparative Examples 3 and 4 show that increased magnesium content has a dose-dependent effect in improving depressive behavior in mice. However, Comparative Examples 5 and 6 show that the effect of improving depressive behavior in mice does not increase further with further increases in magnesium content.

[0098] Mouse defecation experiment Mice were given loperamide (8 mg / kg·d) to induce constipation: 0.5 h after the last administration, mice were given gavage according to the above example, with a gavage dose of 250 mg / (kg·d), and the time of first defecation, fecal weight and fecal water content of mice were recorded.

[0099] Time to first defecation: The time elapsed from the end of gavage to the first defecation.

[0100] Total fecal weight: The total fecal weight excreted by each mouse within 24 hours after gavage (based on the average weight of mice in the group).

[0101] The results of the fecal moisture content % - (fecal wet weight - fecal thousand weight) / fecal wet weight × 100% are shown in Table 3. Table 3 shows the results of animal experiments on the composition's relief of constipation.

[0102] Table 3

[0103] As shown in Table 3, after administering the combination of probiotics, magnesium, and banana powder, the defecation time of mice was significantly improved, the amount of mouse feces increased, and the water content of mouse feces was higher. This indicates that the combination can improve constipation in mice to a certain extent, and the effect is better than using probiotics alone and / or the combination of probiotics and magnesium.

[0104] Comparative Examples 3 and 4 show that the increase in magnesium content has a dose-dependent effect on improving constipation in mice.

[0105] Comparative Examples 5 and 6 show that with further increases in magnesium content, the time of first defecation and the weight of defecation in mice no longer increased, but the water content of feces was >75%, indicating that the mice developed watery diarrhea and that the continuous increase in magnesium content had a side effect on the mice.

[0106] In summary, the improvement effect tends to plateau after the magnesium content exceeds 25% by mass, or when the ratio of magnesium mass to banana powder mass is greater than 5. However, when the magnesium content exceeds 37.5% by mass, or when the ratio of magnesium mass to banana powder mass is greater than or equal to 7.5, side effects occur. Therefore, in this application, as a further solution, the magnesium content ranges from 0.5% to 25% or 0.5% to 37.5%; or, the ratio of magnesium mass to banana powder mass ranges from ≤5 or ≤7.5. Based on the above description and embodiments, it can be understood that, compared with the prior art, this application has the following significant beneficial effects: 1) Multi-target synergistic regulation of the brain-gut axis: This composition achieves comprehensive regulation of neurotransmitter synthesis, intestinal barrier repair, inflammation modulation, and nerve receptor function through the synergistic effect of probiotics, magnesium salts, and banana powder. Probiotics promote the production of short-chain fatty acids (SCFAs), repair the intestinal barrier, and reduce the release of inflammatory factors; magnesium salts regulate NMDA receptor and HPA axis activity, alleviating excessive excitation of the central nervous system; banana powder provides natural neurotransmitter precursors, inhibits MAO-B activity, and increases dopamine and serotonin levels. The synergistic effect of these three components covers multiple key pathways in the regulation of the gut-brain axis, overcoming the limitations of single-component mechanisms.

[0107] 2) Significantly improves mood and cognitive function: Animal experiments have confirmed that this composition can significantly reduce anxiety and depression-like behaviors, increase open-arm exploration time and frequency, and shorten the immobility time during forced swimming, indicating its clear effect on mood regulation. Simultaneously, the composition has no effect on spontaneous activity, suggesting that its ameliorative effect is specific and not achieved through non-specific excitation.

[0108] 3) Effectively improves gastrointestinal function: This composition demonstrates outstanding performance in improving constipation, significantly shortening the time to first bowel movement and increasing stool weight and water content. Probiotics promote intestinal peristalsis by regulating gut microbiota balance and producing SCFAs; magnesium salts relieve constipation through osmosis and relaxation of intestinal smooth muscle; and dietary fiber in banana powder further enhances intestinal peristalsis and water retention capacity. The three components work synergistically to achieve comprehensive improvement in gastrointestinal function.

[0109] 4) High security and wide applicability: All ingredients are naturally derived or recognized as safe food components, avoiding the side effects and addictive potential of chemical drugs. The use of inactivated bacteria further enhances the product's stability and safety, making it suitable for a wide range of people, including children and the elderly. The product is available in various forms, suitable for daily use as a dietary supplement or functional food, improving patient acceptance and adherence.

[0110] 5) Overcome the stigma associated with the illness and improve adherence: Providing emotional and gut health support in the form of food avoids the stigma associated with mental health interventions, making it more acceptable to consumers and encouraging long-term adherence to use, thereby achieving better health improvement results.

[0111] The above description is merely a selection of preferred embodiments of this disclosure and an explanation of the technical principles employed. Those skilled in the art should understand that the scope of the invention involved in the embodiments of this disclosure is not limited to technical solutions formed by specific combinations of the above-described technical features, but should also cover other technical solutions formed by arbitrary combinations of the above-described technical features or their equivalents without departing from the above-described inventive concept. For example, technical solutions formed by substituting the above-described features with (but not limited to) technical features with similar functions disclosed in the embodiments of this disclosure.

Claims

1. An edible composition, characterized in that, The edible composition comprises, by weight parts: Probiotics: 10 to 2900 servings; Magnesium salts: 10 to 450 parts; Banana powder: 1 to 100 servings; The total bacterial count of the probiotics ranges from 1 billion CFU / g to 50 billion CFU / g.

2. The edible composition according to claim 1, characterized in that, The probiotics include one or more of the following: Bifidobacterium longum subsp. Rosell@-175, Bifidobacterium longum 1714, Lactobacillus paracasei Lpc-37, Lactobacillus plantarum CECT7481, Lactobacillus plantarum P-8, Lactobacillus plantarum CECT7481, Lactobacillus rhamnosus HN001, and Bifidobacterium animalis subsp. lactis HN01.

3. The edible composition according to claim 2, characterized in that, The total bacterial count of the probiotics ranges from 20 billion CFU / g to 50 billion CFU / g.

4. The edible composition according to claim 1, characterized in that, The magnesium salts include one or more of the following: magnesium glycinate, magnesium citrate, magnesium malate, magnesium aspartate, magnesium lactate, magnesium gluconate, magnesium taurate, magnesium threonate, magnesium orotic acid, magnesium hydroxide, magnesium carbonate, and magnesium oxide.

5. The edible composition according to claim 4, characterized in that, The mass percentage of magnesium in the edible composition ranges from 0.5% to 50%.

6. The edible composition according to claim 1, characterized in that, The banana powder is made from ripe banana fruit and / or banana peel.

7. The edible composition according to claim 6, characterized in that, The percentage of banana powder by mass ranges from 0.01% to 10%.

8. The edible composition according to claim 1, characterized in that, The edible composition is prepared as at least one of the following: powder, capsule, solid beverage, soft drink, soft capsule, liquid, powder, tablet, granule, and drops.

9. The edible composition according to claim 1, characterized in that, The edible composition is prepared as a part of at least one of powder, capsule, solid beverage, soft drink, soft capsule, liquid, powder, tablet, granule, and drops.

10. An application of the edible composition according to any one of claims 1 to 9 as a food, said food comprising at least: Chocolate, fudge, jelly, filled chocolate, beverages, coffee.

Images